Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

190.40 -2.07 (-1.08%)
Official Closing Price Updated: 7:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
The trillion-dollar club will probably need to make room for at least one Dividend King in the coming years. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Ben & Jerry's Co-Founder Resigns In Protest As Politics Continue To Influence Corporate Exits
Jerry Greenfield, of Ben & Jerry's fame, didn't resign over personal controversy—he quit because his company stopped being political enough. 
Via Benzinga
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
A high yield is only one part of the story when it comes to picking dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Confronts the End of its Talc Legacy with Multi-Billion Dollar Settlements
Johnson & Johnson (NYSE: JNJ) is navigating a critical juncture in its protracted legal battle over talc-based baby powder. The healthcare behemoth has announced a tentative $700 million settlement... 
Via MarketMinute
Topics Bankruptcy Death Lawsuit
J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study
Via Stocktwits
P&G's Q3 2025: Sales Miss Overshadows Earnings Beat Amidst Global Headwinds
Procter & Gamble (NYSE: PG) recently disclosed its fiscal third-quarter 2025 results, presenting a nuanced financial picture that has stirred investor sentiment. While the consumer goods titan managed... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drug
Via Stocktwits
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients
Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients. 
Via Benzinga
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?
The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma. 
Via Investor's Business Daily
Recent Report Shows That Rep. Thomas Kean Bought Up to $45K Worth of Amcor Stock
 
Via Benzinga
8 Dividend Growth Stocks Every Investor Should Consider
These dividend powerhouses compound wealth through decades of consecutive increases and sustainable payout ratios. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Nanobiotix reported melanoma study data showing JNJ-1900 delivered 47.4% response rate, 78.9% disease control, and 14.6 months survival. 
Via Benzinga
Intuitive Surgical: A Steady Hand in a Storm of AI Hype?
In a financial landscape increasingly dominated by the exhilarating, often volatile, narrative of artificial intelligence, Intuitive Surgical (NASDAQ: ISRG) stands as a testament to steady, fundamental... 
Via MarketMinute
Topics Artificial Intelligence Supply Chain
Federal Reserve Navigates Stagflationary Headwinds with Dovish Pivot
Washington D.C. - The U.S. Federal Reserve finds itself at a critical juncture, facing an economic environment that is increasingly raising the specter of "stagflation" – a challenging combination of... 
Via MarketMinute
Topics Economy Supply Chain World Trade
What the Options Market Tells Us About Johnson & Johnson
 
Via Benzinga
The Specter of Stagflation: Is the Economy Headed for Stagnant Growth and High Inflation?
The U.S. Federal Reserve’s recent decision to cut interest rates has sent a tremor of concern through financial markets, sparking fears of a potential return to stagflation—an economic phenomenon... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis. 
Via Benzinga
Intuitive Surgical's Stellar Q2 2025 Performance Propels Robotic Surgery Market Forward
Sunnyvale, CA – September 17, 2025 – Intuitive Surgical (NASDAQ: ISRG), the pioneer and global leader in robotic-assisted surgery, has once again demonstrated its formidable market position with a... 
Via MarketMinute
Topics Artificial Intelligence Supply Chain
A Precarious Ascent: Stock Market Bulls Grapple with Stubborn Inflation and a Cooling Job Market
The financial markets find themselves in a fascinating, if precarious, dance. Despite a recent surge in stock market performance, with the S&P 500 ([SPX]) registering robust gains in recent years,... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Johnson & Johnson (NYSE:JNJ): A Dividend Stock with Lasting Financial Strength
Johnson & Johnson (JNJ) is a top dividend stock with a 2.91% yield, over 10 years of growth, and strong financials for reliable income. 
Via Chartmill
GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America
The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
Navigating the Storm: Investment Strategies for an Unpredictable 2025
The financial landscape is bracing for a turbulent 2025, as expert consensus points towards a significant uptick in market volatility. This anticipated shift, driven by a complex interplay of global... 
Via MarketMinute
Topics Artificial Intelligence Bonds Climate Change
3 Dividend Stocks to Hold Through Market Volatility This Fall
Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall 
Via MarketBeat
Topics Economy
Monetary Easing on the Horizon: Investors Brace for 2025 Rate Cuts, Fueling a Shift to Risk Assets
Central banks worldwide, spearheaded by the U.S. Federal Reserve, are signaling a significant pivot towards monetary easing in 2025. This anticipated shift, driven by a weakening labor market and... 
Via MarketMinute
Topics Bonds Economy Supply Chain
Market Mania Meets Economic Malaise: Record Highs Clash with Persistent Headwinds in Q3 2025
The third quarter of 2025 has been a period of stark contrasts for the global financial markets. While major U.S. stock indices like the S&P 500 and the Dow Jones Industrial Average (DJIA) have soared... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
3 Dividend-Paying ETFs to Buy in September Even If the S&P 500 Sells Off
Dividend-paying growth stocks and covered call ETFs provide opportunities to generate income even in a declining stock market. 
Via The Motley Fool
Topics ETFs Stocks
3 Dividend Growers That Fly Under the Radar
These three companies may have what it takes to continue to build on their strong history of dividend payments even if the economy continues to sour. 
Via MarketBeat
Topics Earnings Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS